Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 139
Filtrar
1.
Kidney Int ; 60(4): 1233-9, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11576337

RESUMEN

BACKGROUND: Autosomal-dominant medullary cystic kidney disease (MCKD) is an interstitial nephropathy characterized by structural renal tubular defects that result in salt wasting and a reduction in urinary concentration. The condition has clinical and morphological similarities to autosomal-recessive juvenile nephronophthisis. Two genes predisposing to MCKD have been localized. MCKD1 on chromosome 1q21 was localized in two Cypriot families, and MCKD2 on chromosome 16p12 was localized in a single Italian family. We have evaluated a large Welsh MCKD family for linkage at these two loci. METHODS: Clinical data and DNA samples were collected from affected family members. Polymorphic microsatellite markers spanning the critical regions on chromosome 1 and chromosome 16 that encompass MCKD1 and MCKD2 were analyzed. Two-point and multipoint LOD scores were calculated. RESULTS: The family fulfilled previously published criteria for the diagnosis of MCKD, but hyperuricemia and gout were not prominent features. Twenty-one affected individuals were identified. Mean age at death or end-stage renal disease was 47 years (37 to 60). Linkage and haplotype analysis generated strongly negative results at MCKD1 on chromosome 1q21 (two-point LOD score = -5.32). Strong evidence of linkage to MCKD2 was generated with a maximum multi-point LOD score of 3.75. CONCLUSION: These results provide the first independent confirmation of a gene predisposing to MCKD on chromosome 16p12 and indicate that mutation of this gene is not restricted to a single family or population. The absence of hyperuricemia and gout in our family indicates that these are not obligatory features of MCKD2 mutations.


Asunto(s)
Mapeo Cromosómico , Cromosomas Humanos Par 16/genética , Riñón Poliquístico Autosómico Dominante/genética , Adulto , Femenino , Ligamiento Genético , Predisposición Genética a la Enfermedad , Humanos , Médula Renal , Escala de Lod , Masculino , Persona de Mediana Edad , Linaje
2.
Kidney Int ; 59(4): 1529-38, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11260417

RESUMEN

BACKGROUND: In a randomized, controlled trial comparing a pH neutral, bicarbonate/lactate (B/L)-buffered PD solution to conventional acidic, lactate-buffered solution (C), the overnight dialysate levels of markers of inflammation/wound healing [hyaluronic acid (HA)], mesothelial cell mass/membrane integrity [cancer antigen 125 (CA125)], and fibrosis [transforming growth factor-beta1 (TGF-beta1) and procollagen I peptides (PICP)] were assessed over a six-month treatment period. METHODS: One hundred six patients were randomized (2:1) to either the B/L group or C group. Overnight effluents were collected at entry into the study (time = 0 all patients on control solution) and then at three and six months after randomization. Aliquots were filtered, stored frozen, and assayed for HA, CA125, TGF-beta1, and PICP. Differences between groups were assessed by repeated-measures analysis of variance for unbalanced data using the SAS procedure MIXED. RESULTS: In patients treated with B/L, there was a significant (P = 0.03) increase in CA125 after six months compared with time = 0 (19.76 +/- 11.8 vs. 24.4 +/- 13.8 U/mL; mean +/- SD; N = 51). In the same group of patients, HA levels were significantly decreased at both three and six months in the B/L-treated group (time = 0, 336.0 +/- 195.2; time = 3 months, 250.6 +/- 167.6; and time = 6 months, 290.5 +/- 224.6 ng/mL; mean +/- SD; P = 0.006, N = 47 and P = 0.003, N = 48, respectively). No significant changes in CA125 or HA levels were observed in the control group. There were no significant changes observed in the levels of PICP or TGF-beta1 in the B/L or C group over the six-month treatment period. CONCLUSIONS: These results suggest that continuous therapy with the B/L solutions modulates the levels of putative markers of peritoneal membrane integrity and inflammation. In the long term, this may positively impact the peritoneal membrane, increasing its life as a dialyzing organ.


Asunto(s)
Bicarbonatos/administración & dosificación , Soluciones para Diálisis/uso terapéutico , Lactatos/administración & dosificación , Diálisis Peritoneal , Adulto , Anciano , Bicarbonatos/uso terapéutico , Antígeno Ca-125/metabolismo , Soluciones para Diálisis/química , Femenino , Humanos , Ácido Hialurónico/metabolismo , Lactatos/uso terapéutico , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/metabolismo , Procolágeno/metabolismo , Factores de Tiempo , Factor de Crecimiento Transformador beta/metabolismo , Factor de Crecimiento Transformador beta1
4.
Adv Ren Replace Ther ; 7(4): 289-301, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11073561

RESUMEN

There is increasing evidence that long-term peritoneal dialysis (PD) is associated with structural changes in the peritoneal membrane. These consist of thickening of the sub-mesothelial space owing to collagen deposition and alterations in small blood vessel morphology. These alterations become more pronounced with duration of PD therapy. These changes are associated with a tendency to increasing small solute transport rate with reduced ultrafiltration. The relationship between these structural and functional changes remains unknown, but the evidence suggests that both peritonitis and exposure to dialysate contribute. The most likely components of the fluid responsible for this effect are glucose and/or its degradation products generated during heat sterilisation. Serial monitoring of peritoneal function is well established, but repeat biopsies are not practical. Effluent markers are not yet of proven value but do alter in response to a change in dialysate composition. Hopefully, a combination of reduced inflammation and more biocompatible fluids will reduce long-term changes in peritoneal membrane structure and function with a consequent improvement in patient and technique survival.


Asunto(s)
Fallo Renal Crónico/patología , Fallo Renal Crónico/terapia , Diálisis Peritoneal , Peritoneo/patología , Humanos , Fallo Renal Crónico/metabolismo , Peritoneo/metabolismo , Esclerosis , Factores de Tiempo , Ultrafiltración
5.
Am J Kidney Dis ; 35(1): 112-21, 2000 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10620552

RESUMEN

The impact on peritoneal macrophage (PMO) function of acidic lactate-buffered (Lac-PDF [PD4]; 40 mmol/L of lactate; pH 5.2) and neutral-pH, bicarbonate-buffered (TB; 38 mmol/L of bicarbonate; pH 7. 3) and bicarbonate/lactate-buffered (TBL; 25 mmol/L of bicarbonate/15 mmol/L of lactate; pH 7.3) peritoneal dialysis fluids (PDFs) was compared during a study of continuous therapy with PD4, TB, or TBL. During a run-in phase of 6 weeks when all patients (n = 15) were treated with their regular dialysis regimen with Lac-PDF, median PMO tumor necrosis factor alpha (TNFalpha) release values were 203.6, 89.9, and 115.5 pg TNFalpha/10(6) PMO in the patients subsequently randomized to the PD4, TB, and TBL treatment groups, respectively. Median stimulated TNFalpha values (serum-treated zymosan [STZ], 10 microgram/mL) were 1,894.6, 567.3, and 554.5 pg TNFalpha/10(6) PMO in the same groups, respectively. During the trial phase of 12 weeks, when the three groups of patients (n = 5 per group) were randomized to continuous treatment with PD4, TB, or TBL, median constitutive TNFalpha release values were 204.7, 131.4, and 155.4 pg TNFalpha/10(6) PMO, respectively. Stimulated TNFalpha values (STZ, 10 microgram/mL) were 1,911, 1,832, and 1,378 pg TNFalpha/10(6) PMO in the same groups, respectively. Repeated-measures analysis of variance comparing the run-in phase with the trial phase showed that PMO TNFalpha release was significantly elevated in patients treated with both TB (P = 0.040) and TBL (P = 0.014) but not in patients treated with Lac-PDF (P = 0. 795). These data suggest that patients continuously exposed to bicarbonate- and bicarbonate/lactate-buffered PDFs might have better preserved PMO function and thus improved host defense status.


Asunto(s)
Bicarbonatos/administración & dosificación , Soluciones para Diálisis , Ácido Láctico/administración & dosificación , Macrófagos Peritoneales/efectos de los fármacos , Diálisis Peritoneal Ambulatoria Continua , Adulto , Anciano , Bicarbonatos/efectos adversos , Femenino , Humanos , Concentración de Iones de Hidrógeno , Ácido Láctico/efectos adversos , Activación de Macrófagos/efectos de los fármacos , Activación de Macrófagos/inmunología , Macrófagos Peritoneales/inmunología , Masculino , Persona de Mediana Edad , Peritonitis/inmunología , Factor de Necrosis Tumoral alfa/metabolismo
7.
Kidney Int ; 54(6): 2234-40, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9853290

RESUMEN

The role of peritoneal dialysis (PD) in renal replacement therapy (RRT) remains unclear. There are no controlled trials to provide hard evidence of its efficacy. Comparative studies with haemodialysis from different centres and countries have given conflicting results even when allowing for case mix. Data from the United States on patients starting or receiving treatment in the late 1980s suggested a worse prognosis for older patients, particularly diabetics receiving PD as compared to HD. Analysis of the USRDS data base for patients starting in the early 1990s shows an improvement in outcome but with no difference in overall mortality. The Canadian registry has recently published data showing a better survival with PD than with HD in the first two years of RRT. Morbidity is similar with both therapies, although hospitalization is increased with PD. Unfortunately long-term technique survival is not as good with PD. However, PD has certain medical advantages, particularly the maintenance of residual renal function that contributes to solute and fluid removal. It may also postpone the onset of amyloidosis. Patients transplanted after previous PD have a decreased risk of early acute renal failure and equally good long-term results when compared to those patients who were on HD before transplantation. The quality of life is as good with PD as with center HD, and there are social advantages to PD including an increased chance of employment, more flexible holidays and avoidance of thrice weekly travel to a dialysis center. PD also has logistical advantages and can be utilized by the majority of new patients. We therefore conclude that PD has potential advantages early in the course of RRT, and should therefore be offered as a first option to all suitable new patients. Whether PD has a major or minor role in later years (> 5) remains unclear.


Asunto(s)
Fallo Renal Crónico/terapia , Diálisis Peritoneal , Estudios de Evaluación como Asunto , Humanos , Calidad de Vida , Diálisis Renal , Terapia de Reemplazo Renal , Resultado del Tratamiento
8.
Nephrol Dial Transplant ; 13(12): 3165-71, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9870483

RESUMEN

BACKGROUND: The combination of a low pH and a high concentration of lactate which is present in most dialysis fluids is found to be cytotoxic in vitro. For these reasons it would seem logical to use a bicarbonate-containing solution and thus automatically provide a solution with a neutral pH. METHODS: A parallel, randomized, open-label, prospective 2-month trial with an optional 4 month extension was undertaken to compare two novel bicarbonate-based solutions; one containing 38 mmol/l of bicarbonate (B), and one containing a mixture of 25 mmol/l bicarbonate and 15 mmol/l of lactate (B/L), with a control solution (C) containing 40 mmol/l lactate. RESULTS: Three groups of 19 (C), 20 (B), and 20 (B/L) patients were recruited and data from approximately 55 patient months were accumulated in each group. The data show that both bicarbonate-based solutions maintain acid-base levels within the normal range, that there were no changes in any of the other blood biochemistry parameters measured in the peritoneal equilibration test or with regard to adequacy of dialysis, and that furthermore, both solutions were well tolerated. CONCLUSIONS: This study showed that either the bicarbonate or bicarbonate/lactate solutions could be utilized efficaciously in patients undergoing CAPD.


Asunto(s)
Bicarbonatos/administración & dosificación , Soluciones para Diálisis/uso terapéutico , Diálisis Peritoneal Ambulatoria Continua , Equilibrio Ácido-Base/efectos de los fármacos , Bicarbonatos/efectos adversos , Transporte Biológico/efectos de los fármacos , Soluciones para Diálisis/efectos adversos , Combinación de Medicamentos , Estudios de Evaluación como Asunto , Femenino , Humanos , Riñón/efectos de los fármacos , Riñón/fisiopatología , Ácido Láctico/administración & dosificación , Ácido Láctico/efectos adversos , Masculino , Persona de Mediana Edad , Peritoneo/metabolismo , Estudios Prospectivos
9.
J Am Soc Nephrol ; 9(8): 1499-506, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9697673

RESUMEN

Peritoneal macrophage (PMO) function was examined ex vivo after their in vivo exposure to either acidic, lactate-buffered solutions (PD4; 40 mM lactate, pH 5.2), bicarbonate/lactate-buffered solution (TBL; 25 mM/15 mM bicarbonate/lactate, pH 7.3), or bicarbonate-buffered solution (TB; 38 mM bicarbonate, pH 7.3), containing either 1.36 or 3.86% glucose. Initial experiments demonstrated that tumor necrosis factor-alpha (TNFalpha) release (assessed by TNF-direct immunoassay [DIA]) from PMO isolated from the peritoneal cavities of patients exposed to conventional fluid (PD4 1.36% glucose) was lowest after 30 min of intraperitoneal dwell (3591+/-1200 versus 28,946+/-9359 for 240-min dwell [pg/ml], n=5, P < 0.05). Five patients were exposed on 3 successive days to PD4, TBL, and TB for 30-min acute dwells containing 1.36% glucose in the first week and 3.86% glucose during the second. PMO TNFalpha release was assessed after ex vitro exposure to lipopolysaccharide (LPS). Exposure of PMO to TBL or TB (1.36% glucose) resulted in a significant increase in the generation of TNFalpha (pg/2 X 10(6) PMO) compared with PD4. TBL: 68,659+/-35,633, TB: 53,682+/-26,536 versus PD4 17,107+/-8996 (LPS 1.0 ng/ml, n=5 patients, P=0.043 versus PD4 for both). PMO that were recovered from PD4 and TB dwells (3.86% glucose) showed no significant difference in TNFalpha secretion (21,661+/-6934 and 23,923+/-9147, respectively). In contrast, exposure to TBL resulted in a significant increase (41,846+/-11,471) compared with PD4 (LPS 1.0 ng/ml, n=5 patients, P=0.043). These data demonstrate enhanced PMO function after in vivo exposure to bicarbonate- and bicarbonate/lactate-buffered solutions. This response was sustained in TBL alone at the highest glucose concentrations. These results suggest that the newer solutions, and particularly bicarbonate/lactate, might improve host defense status in peritoneal dialysis patients.


Asunto(s)
Soluciones para Diálisis/farmacología , Macrófagos Peritoneales/efectos de los fármacos , Macrófagos Peritoneales/metabolismo , Diálisis Peritoneal , Factor de Necrosis Tumoral alfa/metabolismo , Anciano , Bicarbonatos , Tampones (Química) , Femenino , Glucosa , Humanos , Técnicas In Vitro , Lactatos , Lipopolisacáridos/farmacología , Masculino , Persona de Mediana Edad , Diálisis Peritoneal/efectos adversos , Diálisis Peritoneal/métodos , Peritonitis/etiología , Peritonitis/prevención & control
10.
Kidney Int ; 52(3): 607-13, 1997 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-9291178

RESUMEN

To determine the effect of the ACE gene insertion/deletion (I/D) polymorphism, angiotensinogen gene M235T polymorphism and the angiotensin 1 receptor gene A1166C polymorphism on the age of onset of end-stage renal failure (ESRF) in PKD1 adult autosomal-dominant polycystic kidney disease (ADPKD), 189 individuals from 46 families with PKD1 were genotyped for each polymorphism. Of the 189 patients 52 (28%) reached ESRF at an average age of 48 +/- 1 year. In patients genotyped for the ACE gene insertion/deletion polymorphism the frequencies of the DD, ID and II genotypes were similar to those expected from Hardy Weinberg equilibrium. In patients with ESRF there was an excess of patients homozygous for the deletion allele (DD: 48% chi2 = 9.97 (1df) P = 0.002). Cumulative renal survival was significantly reduced among those with DD genotype compared to ID and II genotypes. The estimated mean renal survival (95% confidence intervals) were: DD, 52 years [48, 57]; II, 59 years [54, 63]; ID, 64 years [56, 72]; chi2 = 6.13 (1df) P = 0.013, DD versus ID/II. The mean age of renal failure was significantly younger in the DD genotype compared to ID and II genotypes (DD, ID, and II: 44 +/- 2, 49 +/- 2 and 54 +/- 3 years, respectively; P < 0.05 DD vs. ID, P < 0.05 DD vs. II). Ten of the eleven patients who reached ESRF before the age of 40 were homozygous for the deletion allele. The relative risk for ESRF below the age 40 for DD genotype was 17. For all ages there was an overall increased risk of 1.4 for ESRF with the DD genotype. There was no interaction between age of onset of ESRF and either the angiotensinogen M235T allele or angiotensin 1 receptor A1166C polymorphism. This study strongly suggests that PKD 1 patients homozygous for the deletion allele of the ACE gene are at increased risk of developing ESRF at a early age.


Asunto(s)
Eliminación de Gen , Fallo Renal Crónico/genética , Peptidil-Dipeptidasa A/genética , Riñón Poliquístico Autosómico Dominante/complicaciones , Riñón Poliquístico Autosómico Dominante/genética , Polimorfismo Genético/genética , Adulto , Edad de Inicio , Femenino , Humanos , Fallo Renal Crónico/epidemiología , Masculino
12.
Perit Dial Int ; 17(1): 48-51, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9068022

RESUMEN

OBJECTIVE: To evaluate the safety and efficacy of bicarbonate- and bicarbonate/lactate-based PD fluids. DESIGN: A randomly allocated prospective controlled trial lasting eight weeks. SETTING: Five renal units in Europe. PATIENTS: Individuals who have been treated by CAPD for at least three months and who have had at least one month's therapy with 40 mmol/L lactate PD fluid. Those with recent infection, diabetes or other serious illness are excluded. Forty-seven individuals have entered the study so far. INTERVENTIONS: Patients are randomly allocated to three groups. Group 1 receive 40 mmol/L lactate dialysate, Group 2 are given 38 mmol/L bicarbonate fluid and Group 3 are tested with a 25 mmol/L bicarbonate and 15 mmol/L lactate dialysate. OUTCOME MEASURES: The primary outcome measure is the plasma bicarbonate level. Adverse events and ease of use of the two-chambered bags used by Groups 2 and 3 are also being assessed. RESULTS: To date, plasma bicarbonate levels have been the same in all treatment groups up to the end of the trial period. There are no differences in serum lactate levels. No side effects are attributable to the test fluids. The patients have managed the two-chambered bags successfully. CONCLUSION: This trial is still ongoing, but to date, neutral bicarbonate based fluids have been as effective as lactate dialysate in treating uremic acidosis.


Asunto(s)
Bicarbonatos , Soluciones para Diálisis , Ácido Láctico , Diálisis Peritoneal Ambulatoria Continua , Adulto , Anciano , Bicarbonatos/sangre , Soluciones para Diálisis/efectos adversos , Humanos , Ácido Láctico/sangre , Persona de Mediana Edad , Estudios Prospectivos
13.
J R Coll Physicians Lond ; 31(1): 27-31, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9044194

RESUMEN

Blood pressure control is important and lower target values are required in those with proteinuria. ACEI are suitable agents provided the doctor is aware of the risks of renovascular disease in the elderly. Renal function should be checked after two weeks treatment; deterioration calls for cessation of ACEI treatment and investigation for renal arterial disease. Low protein diet should not be used routinely but high protein diet should be avoided. If a highly motivated patient wishes to try protein reduction in case it is beneficial, no less than 0.6 g protein/day should be prescribed. The patient must be reviewed regularly by a specialist dietitian who can check nutritional state. Regular medical follow-up is essential; it has been shown to slow progression of renal failure probably because patients become more compliant with therapy, particularly antihypertensives. When should this follow-up be transferred to the renal unit? Studies from many countries have shown that late referral and/or emergency first dialysis are associated with substantially increased mortality and morbidity. Patients in whom the primary diagnosis is in doubt should be seen early; those in whom the cause is known, conservative treatment in place and without uraemic symptom should be transferred by the time the serum creatinine reaches 300 mumol/l.


Asunto(s)
Fallo Renal Crónico/terapia , Anciano , Proteínas en la Dieta/administración & dosificación , Humanos
14.
J Lab Clin Med ; 129(1): 23-34, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9011588

RESUMEN

Peritoneal macrophages (PMOs) are important components of the host defense against microbial infection in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Incubation of human PMOs with cell-free supernatant (BFS), prepared from Staphylococcus aureus, inhibited prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) production. Slot-blot analysis of cyclooxygenase-1 (Cox-1) and Cox-2 demonstrated a decrease in both Cox-1 (29%) and, to a greater extent, Cox-2 (65%) protein expression after BFS stimulation. When competitive polymerase chain reaction (PCR) was used, the peak levels of Cox-1 and Cox-2 messenger ribonucleic acid (mRNA) in unstimulated PMOs were 0.304+/-0.13 pmol/L and 9.61+/-2.84 pmol/L (mean+/-SEM, n = 3), respectively. After exposure of samples to BFS for 30 minutes, the level of Cox-2 mRNA was reduced to 0.59+/-0.449 pmol/L (16-fold reduction, p < 0.05), and the level of Cox-1 mRNA was reduced to 0.02+/-0.002 pmol/L (15-fold reduction, p < 0.05). In contrast, these same PMOs showed an increased expression of IL-6 mRNA and increased secretion of IL-6 protein. These results indicate that prostaglandin production in PMOs is regulated by alterations in both immunoreactive Cox-1 and Cox-2. The down-regulation of Cox metabolism in these cells is primarily related to the delayed and depressed increase in the Cox-2 gene product.


Asunto(s)
Exotoxinas/farmacología , Isoenzimas/efectos de los fármacos , Macrófagos Peritoneales/enzimología , Diálisis Peritoneal Ambulatoria Continua , Prostaglandina-Endoperóxido Sintasas/efectos de los fármacos , Staphylococcus aureus/metabolismo , Adolescente , Adulto , Anciano , Anticuerpos/análisis , Técnicas de Cultivo de Célula , Ciclooxigenasa 1 , Ciclooxigenasa 2 , Regulación hacia Abajo/fisiología , Eicosanoides/biosíntesis , Femenino , Humanos , Isoenzimas/inmunología , Isoenzimas/metabolismo , Masculino , Proteínas de la Membrana , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa/métodos , Prostaglandina-Endoperóxido Sintasas/inmunología , Prostaglandina-Endoperóxido Sintasas/metabolismo , ARN Mensajero/biosíntesis , ARN Mensajero/efectos de los fármacos , Staphylococcus aureus/aislamiento & purificación
15.
Kidney Int ; 50(4): 1212-23, 1996 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8887280

RESUMEN

The initiation of peritonitis is accompanied by a massive increase in intraperitoneal levels of IL-6. The source of this cytokine and the mechanism by which its levels are increased so dramatically are unknown. We examined the mechanism of IL-6 secretion by HPMC exposed to the milicu present in the peritoneal cavity during the initiation of inflammation. Exposure of HPMC to spent peritoneal dialysis effluent (PDE) or IL-1 beta resulted in a time- and dose-dependent increase in IL-6 secretion. After 24 hours the IL-6 release (pg/microgram cell protein) was increased from 5.0 +/- 0.8 in control cells to 16.0 +/- 2.4 and to 83.8 +/- 17.4 in HPMC treated with PDE and IL-1 beta (1000 pg/ml), respectively (N = 5, P < 0.05). If, however, PDE and IL-1 beta were combined, then the secretion of IL-6 was synergistically increased to 747.7 +/- 349.9 (P < 0.05 vs. expected additive value). The same effect was evident when PDE was combined with TNF alpha or mixed with peritoneal macrophage conditioned medium. These changes were not a reflection of HPMC proliferation as estimated by 3H-thymidine incorporation. The "superinduction" of IL-6 release was associated both with the induction and stabilization of IL-6 mRNA. Competitive PCR demonstrated that the amount of IL-6 mRNA (fM/microgram total RNA) was increased from 0.35 +/- 0.13 in control cells to 11.66 +/- 3.89 and to 10.83 +/- 5.17 in HPMC treated with PDE and IL-1 beta (100 pg/ml), respectively (N = 5, P < 0.05). The combination of PDE + IL-1 beta synergistically increased IL-6 mRNA levels to 56.33 +/- 8.79 (P < 0.05 vs. additive value). RNA stability experiments using actinomycin D revealed that the half life of IL-6 mRNA (hours) was increased from 2.8 hours in control cells to 6.7 and 9.4 in HPMC exposed to PDE and IL-1 beta, respectively. The combination of PDE together with IL-1 beta resulted in a prolonged stabilization of IL-6 mRNA with levels remaining constant over the 12 hours of the experiment. These data demonstrate that HPMC IL-6 synthesis can be synergistically amplified in the presence of peritoneal dialysis effluent and PMO-derived cytokines. The results suggest that the peritoneal mesothelium may be responsible for the dramatic rise in IL-6 levels seen during the initial stages of CAPD peritonitis.


Asunto(s)
Epitelio/metabolismo , Regulación de la Expresión Génica , Interleucina-6/biosíntesis , Interleucina-6/genética , División Celular/efectos de los fármacos , Células Cultivadas , Medios de Cultivo Condicionados/farmacología , Cicloheximida/farmacología , Dactinomicina/farmacología , Soluciones para Diálisis/farmacología , Relación Dosis-Respuesta a Droga , Electroforesis en Gel de Agar , Células Epiteliales , Epitelio/efectos de los fármacos , Humanos , Interleucina-1/farmacología , Macrófagos Peritoneales/metabolismo , Modelos Biológicos , Cavidad Peritoneal/citología , Peritonitis/etiología , Reacción en Cadena de la Polimerasa , ARN Mensajero/análisis , Receptores de Interleucina-1/antagonistas & inhibidores , Factores de Tiempo
16.
Kidney Int ; 50(4): 1337-43, 1996 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8887296

RESUMEN

The effect of several different growth factors and cytokines on the synthesis of hyaluronan (HA) by human peritoneal mesothelial cells (HPMC) was investigated. Growth arrested HPMC synthesized low levels of HA, but co-culture with PDGF-bb, TGF-beta 1, TNF-alpha, and IL-6 at a concentration of 10 ng/ml all increased HA synthesis between two- to three-fold. At the same concentration IL-1 beta significantly increased the synthesis eight-fold (N = 3; P < 0.05). The effect of IL-1 beta was also dose- and time-dependent and could be totally negated with interleukin-1 receptor antagonist (IL-1 beta RcA). Non-infected and infected dialysate from patients receiving CAPD was also found to stimulate HA synthesis by HPMC. The levels found with non-infected fluid were 4 x 10(4) dpm/ml (N = 6) and 12.9 x 10(4) dpm/ml (N = 6; P < 0.002) and 8.7 x 10(4) dpm/ml (N = 6; P < 0.003) for infected fluid collected one and two days after the commencement of peritonitis. IL-1 beta RcA dramatically reduced the effect of infected but not non-infected dialysate. These results provide new insights into the manner in which HA synthesis is controlled in the mesothelium and suggest that IL-1 beta is a key cytokine in the inflammatory response in CAPD patients.


Asunto(s)
Ácido Hialurónico/biosíntesis , Interleucina-1/farmacología , Cavidad Peritoneal/citología , Diálisis Peritoneal Ambulatoria Continua , Peritonitis/metabolismo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Células Cultivadas , Citocinas/farmacología , Soluciones para Diálisis/farmacología , Células Epiteliales , Epitelio/efectos de los fármacos , Hemoglobinas , Humanos , Ácido Hialurónico/química , Persona de Mediana Edad
17.
Am J Physiol ; 271(2 Pt 2): F374-81, 1996 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-8770169

RESUMEN

The vasoactive nucleoside adenosine has an important regulatory influence on most aspects of renal function in experimental animals. In this study, we evaluated the effects of intravenous adenosine on systemic and renal hemodynamics, tubular function, and plasma renin concentration in 10 healthy male subjects. Each of the subjects received two intravenous infusions of adenosine (70 micrograms.kg-1.min-1) and saline on three separate study days. There was no significant change in systemic blood pressure in response to adenosine, although there was a significant rise in heart rate postcommencement of adenosine (61.5 +/- 2.9 to 78.0 +/- 7.9 beats/min, 1 h postcommencement of adenosine on day 1, P < 0.01 vs. saline). There was a significant decline in 51Cr-EDTA clearance (glomerular filtration rate) (118.5 +/- 13.2 to 88.0 +/- 8.3 ml/min, P < 0.05 vs. saline) and filtration fraction (19.4 +/- 1.01 to 16.0 +/- 1.03%, P < 0.01 vs. saline) 1 h postcommencement of adenosine, although there was no significant change in 125I-hippuran clearance (effective renal plasma flow). Urine flow rate and osmolar and free water clearance decreased significantly in response to adenosine (particularly on study day 1). There was, in addition, a significant reduction in absolute and fractional excretion rates of sodium, lithium, phosphate, uric acid, chloride, and urea in response to adenosine. There was a rise in plasma renin concentration in response to adenosine, reaching levels of statistical significance on study day 1 (15.0 +/- 2.02 to 22.2 +/- 2.00 microU/ml, 1 h postcommencement of adenosine; P < 0.05 vs. saline). These data are consistent with observations in experimental animals and complement the results of previous studies in man using a selective adenosine A1-receptor antagonist, thereby confirming that adenosine has a significant regulatory influence on human renal function.


Asunto(s)
Adenosina/farmacología , Riñón/efectos de los fármacos , Riñón/fisiología , Adulto , Hemodinámica/efectos de los fármacos , Humanos , Inyecciones Intravenosas , Túbulos Renales/efectos de los fármacos , Túbulos Renales/fisiología , Masculino , Concentración Osmolar , Valores de Referencia , Circulación Renal/efectos de los fármacos , Renina/sangre
18.
Kidney Int ; 49(5): 1447-56, 1996 May.
Artículo en Inglés | MEDLINE | ID: mdl-8731113

RESUMEN

The present study compares the effects of lactate and bicarbonate buffered PDF on human neutrophil (PMN) and human peritoneal mesothelial cell (HPMC) viability and function. Acute exposure of PMN to lactate buffered PDF at pH 5.5 (CAPD 2, 1.5% and CAPD 3, 4.25% glucose) resulted in significant reductions in cellular ATP levels, the phagocytosis of serum treated zymosan (STZ) and respiratory burst activation (CL). Exposure of PMN to bicarbonate buffered PDF (BIC 20, 1.5% glucose and BIC 30, 4.25% glucose both at pH 7.2) had no significant effect on cell viability or the CL response. Phagocytosis was, however, depressed significantly more following exposure to BIC 30 than BIC 20. PMN cellular ATP levels and phagocytosis were significantly better in cells exposed to BIC 30 than to CAPD 3 at pH 7.4 (P = 0.043 for both). Pre-exposure of HPMC to CAPD 2, CAPD 3 or BIC 30 for 30 minutes resulted in a significant reduction in cellular ATP content compared to control medium. Pre-exposure to BIC 20 did not result in a reduction in HPMC ATP levels. HPMC synthesis of IL-6 was unaffected by 15 or 30 minutes pre-exposure to BIC 20 or BIC 30, in contrast pre-exposure to CAPD 2 or CAPD 3 for 15 or 30 minutes resulted in a significant reduction in stimulated IL-6 synthesis (24.5 +/- 3.01 and 32.3 +/- 5.0 vs. 43.9 +/- 10 pg/microgram cell protein in M199, N = 6; P = 0.02). Neutralization of the pH of CAPD 2 and CAPD 3 resulted in normalization of HPMC IL-6 secretion. Analysis of IL-6 mRNA expression in control, BIC 20 and 30 pre-treated HPMC subsequently stimulated with IL-1 beta revealed no differences in the expression of the IL-6 specific 465 base pair transcripts. The improved cellular function in bicarbonate buffered PDF indicates potentially improved host defence status and preservation of the peritoneal membrane in CAPD patients.


Asunto(s)
Soluciones para Diálisis/química , Diálisis Peritoneal Ambulatoria Continua/métodos , Adenosina Trifosfato/metabolismo , Secuencia de Bases , Bicarbonatos , Materiales Biocompatibles , Tampones (Química) , Cartilla de ADN/genética , Epitelio/patología , Epitelio/fisiopatología , Humanos , Concentración de Iones de Hidrógeno , Técnicas In Vitro , Interleucina-6/genética , Fallo Renal Crónico/patología , Fallo Renal Crónico/fisiopatología , Fallo Renal Crónico/terapia , Mediciones Luminiscentes , Datos de Secuencia Molecular , Neutrófilos/fisiología , Fagocitosis , ARN Mensajero/genética , ARN Mensajero/metabolismo , Staphylococcus aureus/inmunología , Staphylococcus epidermidis/inmunología
19.
Br J Pharmacol ; 117(5): 879-84, 1996 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-8851505

RESUMEN

1. The clinical application of cyclosporin as an immunosuppressive agent is limited by its nephrotoxicity. 2. The effect of FK453, a selective A1-receptor antagonist, administered twice daily to rats at a dose of 100 mg kg-1 was assessed on the development of nephrotoxicity induced by cyclosporin (10 mg kg-1 i.p. daily) administered for 14 days. The effects of nifedipine administered twice daily (0.3 mg kg-1 s.c.) for 14 days, on cyclosporin nephrotoxicity were also studied. 3. Cyclosporin induced a 46.58% and 35.78% decline in glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) respectively and a reduction of 16.69% in filtration fraction (FF). Co-administration of FK453 resulted in falls of 30.5%, 18.59% and 14.7% in GFR, ERPF and FF respectively, the former two significantly less than the falls seen with cyclosporin (CyA) alone (P < 0.05 vs CyA, ANOVA). 4. Nifedipine appeared to have a more pronounced protective effect resulting in a decline of only 20.91% in GFR, with no significant change in ERPF (increase of 0.93%) when co-administered with CyA. 5. These observations indicate adenosine plays a minor role in the pathophysiology of CyA nephrotoxicity.


Asunto(s)
Ciclosporina/toxicidad , Inmunosupresores/toxicidad , Enfermedades Renales/prevención & control , Antagonistas Purinérgicos , Pirazoles/farmacología , Piridinas/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Interacciones Farmacológicas , Tasa de Filtración Glomerular/efectos de los fármacos , Enfermedades Renales/inducido químicamente , Masculino , Nifedipino/farmacología , Ratas , Ratas Sprague-Dawley , Flujo Plasmático Renal Efectivo/efectos de los fármacos , Vasodilatadores/farmacología
20.
Exp Nephrol ; 4(1): 26-36, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8788597

RESUMEN

Endogenous adenosine has been postulated to have a pathophysiological role both in the initiation and persistence of acute renal failure. The recent advent of selective adenosine receptor antagonists suitable for clinical studies now makes it possible to assess the influence of this vasoactive compound in chronic renal disease. In this study we evaluated the effects of FK453, a non-xanthine selective adenosine A1 receptor antagonist on renal haemodynamics, tubular function and plasma renin release in two groups of patients with stable chronic renal disease. Group I (n = 6) consisted of patients with creatinine clearance > or = 71 ml/min and group II (n = 7) patients with moderate renal impairment (creatinine clearance 31-70 ml/min). Each patient received two single oral doses of FK453 (50 and 200 mg) and one matched placebo dose in a random order, each on separate study days. Renal haemodynamics, tubular function and plasma renin concentrations were assessed at baseline and after the dose on each study day. There were no significant changes in mean arterial blood pressure, effective renal plasma flow (clearance of 125I-hippuran) or glomerular filtration rate (clearance of 51Cr-EDTA) in response to FK453 in either group. In contrast, there were statistically significant increases in urine flow rate and osmolar clearance, as well as absolute and fractional sodium, phosphate, bicarbonate, lithium, uric acid, magnesium and chloride excretion in response to FK453 in both groups of patients. There was, in addition, a significant increase in the plasma renin concentration in response to FK453 in both groups. These data would be consistent with a regulatory role for adenosine in chronic renal disease in the control of tubular function, especially proximal, as well as plasma renin release by activation of the A1 receptor.


Asunto(s)
Adenosina/fisiología , Enfermedades Renales/fisiopatología , Adulto , Enfermedad Crónica , Diuresis/efectos de los fármacos , Método Doble Ciego , Electrólitos/orina , Femenino , Tasa de Filtración Glomerular/efectos de los fármacos , Humanos , Túbulos Renales/fisiopatología , Masculino , Persona de Mediana Edad , Natriuresis/efectos de los fármacos , Concentración Osmolar , Antagonistas de Receptores Purinérgicos P1 , Pirazoles/farmacología , Piridinas/farmacología , Circulación Renal , Flujo Plasmático Renal Efectivo/efectos de los fármacos , Renina/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA